Stocks Rise on November 29 On Predictable Volatility Crush

This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.

Otherwise, enjoy the column!

Subscribe to the Monster Stock Market Commentary and join the 2,436 subscribers getting it for FREE every day!


Stocks – NONE


Mike’s Reading The Markets (RTM) Premium Content – $45/MONTH OR $400/YEAR – The First 2-weeks are FREE to try AND get 20% off!



Stocks jumped on November 29 as volatility came down sharply. I noted this was highly likely on Sunday, but the S&P 500 wasn’t able to get up to 4700. Instead, it stalled at 4,675. The VIX jumped too much on Friday, and this snapback was obvious once we didn’t get a significant drop at the open.

S&P 500 (SPY)

The IV crush pushed the S&P 500 higher to 4675, which was a resistance level, and that is where it stopped rising. It was also the 61.8% retracement of what I believe was wave three down; therefore, today’s up move could be the completion of wave 4. Thus, we should start wave five tonight or tomorrow in the futures, resulting in that drop to support I have looked for at 4530. Let’s see what happens first before we think further out.


There is a broadening wedge right now in the Qs, and these broadening wedges have been breaking in the direction of the previous move. The broadening wedge going into October was preceded by a rising trend, which led to a breakout. This wedge was proceeded by a down move and should result in a move down to around $383.

High Yield (HYG)

All the recent gaps in the HYG are now filled, except for the lower one. That corresponds nicely to the predicted moves more down in the SPX and QQQ.

Biotech (XBI)

The Biotech ETF (XBI) is close to breaking a significant support level here, $115. It could set up a drop back to $100 over time. It is terrible news for those Russell 2000 fans, too, because many biotech stocks help move the Russell around.


Meanwhile, the risk appetite in the market may be ready to take a turn for the worse, based on the ultimate risk-on/risk-off gauge. The biotech (XBI)/Utility (XLU) ratio has a giant reverse Head and Shoulder pattern present and is about to break the neckline, up. It would mean the XBI underperforms XLU; it is probably not a good sign of what’s to come anytime that happens.

Anyway, that’s all for today. I do not see anything for individual stocks today.


Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and, unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future results.